Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by riva… [+2382 chars]